nach oben

Cancer and Metastasis Reviews

Erschienen in:

04.06.2018

The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis

verfasst von: Typhaine Anquetil, Bernard Payrastre, Marie-Pierre Gratacap, Julien Viaud

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2018

Einloggen, um Zugang zu erhalten

Abstract

Our knowledge on the role of the different lipid messengers produced by phosphoinositide 3-kinases (PI3Ks) in normal and cancer cells as well as in platelets during arterial thrombosis has greatly expanded these last 15 years. PI3Ks are a family of lipid kinases that catalyze the phosphorylation of the D3 position of the inositol ring of phosphoinositides to produce phosphatidylinositol 3-phosphate (PtdIns3P), phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P₂), and phosphatidylinositol-3,4,5 trisphosphate (PtdIns(3,4,5)P₃). These D3-phosphoinositides act as intracellular messengers recruiting effector proteins involved in the control of diverse cellular functions including survival, proliferation, migration, membrane trafficking, and cytoskeleton dynamics. The current idea is that the different isoforms of PI3Ks produce specific pools of lipids that regulate in time and space, at the membrane/cytosol interface, the formation of appropriate functional protein complexes. Dysregulation of PI3K-dependent pathways is directly involved in the etiology of several pathologies including cancers where the PI3K/AKT/mTORC1 axis is frequently aberrantly activated. Moreover, PtdIns(3,4,5)P₃ production has been shown to play an essential role in platelet functions, particularly in the formation of a stable platelet thrombus at high shear rate. Therefore, PI3Ks are attractive therapeutic targets in the treatment of cancer and arterial thrombosis. In this review, we will discuss the role of the different lipid products of PI3K isoforms in the context of cancer and thrombosis and the development of selective PI3Ks inhibitors in the treatment of these diseases.

Balla, T. (2013). Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiological Reviews, 93(3), 1019–1137. https://doi.org/10.1152/physrev.00028.2012.PubMedPubMedCentralCrossRef

Viaud, J., Mansour, R., Antkowiak, A., Mujalli, A., Valet, C., Chicanne, G., et al. (2016). Phosphoinositides: important lipids in the coordination of cell dynamics. Biochimie, 125, 250–258. https://doi.org/10.1016/j.biochi.2015.09.005.PubMedCrossRef

Choy, C. H., Han, B. K., & Botelho, R. J. (2017). Phosphoinositide diversity, distribution, and effector function: stepping out of the box. Bioessays, 39(12), doi: 10.1002/bies.201700121.

Hammond, G. R., & Balla, T. (2014). A tail of new lipids. The EMBO Journal, 33(19), 2140–2141. https://doi.org/10.15252/embj.201489773.PubMedPubMedCentralCrossRef

Bunney, T. D., & Katan, M. (2010). Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nature Reviews Cancer, 10(5), 342–352. https://doi.org/10.1038/nrc2842.PubMedCrossRef

Furie, B., & Furie, B. C. (2005). Thrombus formation in vivo. The Journal of Clinical Investigation, 115(12), 3355–3362. https://doi.org/10.1172/JCI26987.PubMedPubMedCentralCrossRef

Li, J. L., Zarbock, A., & Hidalgo, A. (2017). Platelets as autonomous drones for hemostatic and immune surveillance. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20170879.

Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., et al. (2005). PI 3-kinase p110beta: a new target for antithrombotic therapy. Nature Medicine, 11(5), 507–514. https://doi.org/10.1038/nm1232.PubMedCrossRef

Laurent, P. A., Severin, S., Hechler, B., Vanhaesebroeck, B., Payrastre, B., & Gratacap, M. P. (2015). Platelet PI3Kbeta and GSK3 regulate thrombus stability at a high shear rate. Blood, 125(5), 881–888. https://doi.org/10.1182/blood-2014-07-588335.PubMedCrossRef

10.

Laurent, P. A., Severin, S., Gratacap, M. P., & Payrastre, B. (2014). Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. Advances in Biological Regulation, 54, 162–174. https://doi.org/10.1016/j.jbior.2013.09.006.PubMedCrossRef

11.

Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nature Reviews. Molecular Cell Biology, 11(5), 329–341. https://doi.org/10.1038/nrm2882.PubMedCrossRef

12.

Krugmann, S., Anderson, K. E., Ridley, S. H., Risso, N., McGregor, A., Coadwell, J., et al. (2002). Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. Molecular Cell, 9(1), 95–108.PubMedCrossRef

13.

Catimel, B., Yin, M. X., Schieber, C., Condron, M., Patsiouras, H., Catimel, J., et al. (2009). PI(3,4,5)P3 Interactome. Journal of Proteome Research, 8(7), 3712–3726. https://doi.org/10.1021/pr900320a.PubMedCrossRef

14.

Durrant, T. N., Hutchinson, J. L., Heesom, K. J., Anderson, K. E., Stephens, L. R., Hawkins, P. T., et al. (2017). In-depth PtdIns(3,4,5)P3 signalosome analysis identifies DAPP1 as a negative regulator of GPVI-driven platelet function. Blood Advances, 1(14), 918–932. https://doi.org/10.1182/bloodadvances.2017005173.PubMedPubMedCentralCrossRef

15.

Woulfe, D. S. (2010). Akt signaling in platelets and thrombosis. Expert Review of Hematology, 3(1), 81–91. https://doi.org/10.1586/ehm.09.75.PubMedPubMedCentralCrossRef

16.

Guidetti, G. F., Canobbio, I., & Torti, M. (2015). PI3K/Akt in platelet integrin signaling and implications in thrombosis. Advances in Biological Regulation, 59, 36–52. https://doi.org/10.1016/j.jbior.2015.06.001.PubMedCrossRef

17.

Cullen, P. J., & Venkateswarlu, K. (1999). Potential regulation of ADP-ribosylation factor 6 signalling by phosphatidylinositol 3,4,5-trisphosphate. Biochemical Society Transactions, 27(4), 683–689.PubMedCrossRef

18.

Viaud, J., Gaits-Iacovoni, F., & Payrastre, B. (2012). Regulation of the DH-PH tandem of guanine nucleotide exchange factor for Rho GTPases by phosphoinositides. Advances in Biological Regulation, 52(2), 303–314. https://doi.org/10.1016/j.jbior.2012.04.001.PubMedCrossRef

19.

Campa, F., Yoon, H. Y., Ha, V. L., Szentpetery, Z., Balla, T., & Randazzo, P. A. (2009). A PH domain in the Arf GTPase-activating protein (GAP) ARAP1 binds phosphatidylinositol 3,4,5-trisphosphate and regulates Arf GAP activity independently of recruitment to the plasma membranes. The Journal of Biological Chemistry, 284(41), 28069–28083. https://doi.org/10.1074/jbc.M109.028266.PubMedPubMedCentralCrossRef

20.

Miura, K., Jacques, K. M., Stauffer, S., Kubosaki, A., Zhu, K., Hirsch, D. S., et al. (2002). ARAP1: a point of convergence for Arf and Rho signaling. Molecular Cell, 9(1), 109–119.PubMedCrossRef

21.

Battram, A. M., Durrant, T. N., Agbani, E. O., Heesom, K. J., Paul, D. S., Piatt, R., et al. (2017). The phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) binder Rasa3 regulates phosphoinositide 3-kinase (PI3K)-dependent integrin alphaIIbbeta3 outside-in signaling. The Journal of Biological Chemistry, 292(5), 1691–1704. https://doi.org/10.1074/jbc.M116.746867.PubMedCrossRef

22.

Scharenberg, A. M., El-Hillal, O., Fruman, D. A., Beitz, L. O., Li, Z., Lin, S., et al. (1998). Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. The EMBO Journal, 17(7), 1961–1972. https://doi.org/10.1093/emboj/17.7.1961.PubMedPubMedCentralCrossRef

23.

Schmidt, U., Boucheron, N., Unger, B., & Ellmeier, W. (2004). The role of Tec family kinases in myeloid cells. International Archives of Allergy and Immunology, 134(1), 65–78. https://doi.org/10.1159/000078339.PubMedCrossRef

24.

Li, H., & Marshall, A. J. (2015). Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: a distinct branch of PI3K signaling. Cellular Signalling, 27(9), 1789–1798. https://doi.org/10.1016/j.cellsig.2015.05.013.PubMedCrossRef

25.

Hawkins, P. T., & Stephens, L. R. (2016). Emerging evidence of signalling roles for PI(3,4)P2 in class I and II PI3K-regulated pathways. Biochemical Society Transactions, 44(1), 307–314. https://doi.org/10.1042/BST20150248.PubMedCrossRef

26.

Posor, Y., Eichhorn-Gruenig, M., Puchkov, D., Schoneberg, J., Ullrich, A., Lampe, A., et al. (2013). Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. Nature, 499(7457), 233–237. https://doi.org/10.1038/nature12360.PubMedCrossRef

27.

Marat, A. L., Wallroth, A., Lo, W. T., Muller, R., Norata, G. D., Falasca, M., et al. (2017). mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate. Science, 356(6341), 968–972. https://doi.org/10.1126/science.aaf8310.PubMedCrossRef

28.

Xie, J., Erneux, C., & Pirson, I. (2013). How does SHIP1/2 balance PtdIns(3,4)P2 and does it signal independently of its phosphatase activity? Bioessays, 35(8), 733–743. https://doi.org/10.1002/bies.201200168.PubMedCrossRef

29.

Wullschleger, S., Wasserman, D. H., Gray, A., Sakamoto, K., & Alessi, D. R. (2011). Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis. The Biochemical Journal, 434(2), 265–274. https://doi.org/10.1042/BJ20102012.PubMedPubMedCentralCrossRef

30.

Krause, M., Leslie, J. D., Stewart, M., Lafuente, E. M., Valderrama, F., Jagannathan, R., et al. (2004). Lamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics. Developmental Cell, 7(4), 571–583. https://doi.org/10.1016/j.devcel.2004.07.024.PubMedCrossRef

31.

Yoshinaga, S., Ohkubo, T., Sasaki, S., Nuriya, M., Ogawa, Y., Yasui, M., et al. (2012). A phosphatidylinositol lipids system, lamellipodin, and Ena/VASP regulate dynamic morphology of multipolar migrating cells in the developing cerebral cortex. The Journal of Neuroscience, 32(34), 11643–11656. https://doi.org/10.1523/JNEUROSCI.0738-12.2012.PubMedCrossRef

32.

Boucrot, E., Ferreira, A. P., Almeida-Souza, L., Debard, S., Vallis, Y., Howard, G., et al. (2015). Endophilin marks and controls a clathrin-independent endocytic pathway. Nature, 517(7535), 460–465. https://doi.org/10.1038/nature14067.PubMedCrossRef

33.

Oikawa, T., Itoh, T., & Takenawa, T. (2008). Sequential signals toward podosome formation in NIH-src cells. The Journal of Cell Biology, 182(1), 157–169. https://doi.org/10.1083/jcb.200801042.PubMedPubMedCentralCrossRef

34.

Sharma, V. P., Eddy, R., Entenberg, D., Kai, M., Gertler, F. B., & Condeelis, J. (2013). Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Current Biology, 23(21), 2079–2089. https://doi.org/10.1016/j.cub.2013.08.044.PubMedCrossRef

35.

Falasca, M., Hughes, W. E., Dominguez, V., Sala, G., Fostira, F., Fang, M. Q., et al. (2007). The role of phosphoinositide 3-kinase C2alpha in insulin signaling. The Journal of Biological Chemistry, 282(38), 28226–28236. https://doi.org/10.1074/jbc.M704357200.PubMedCrossRef

36.

Valet, C., Chicanne, G., Severac, C., Chaussade, C., Whitehead, M. A., Cabou, C., et al. (2015). Essential role of class II PI3K-C2alpha in platelet membrane morphology. Blood, 126(9), 1128–1137. https://doi.org/10.1182/blood-2015-03-636670.PubMedCrossRef

37.

Alliouachene, S., Bilanges, B., Chicanne, G., Anderson, K. E., Pearce, W., Ali, K., et al. (2015). Inactivation of the class II PI3K-C2beta potentiates insulin signaling and sensitivity. Cell Reports, 13(9), 1881–1894. https://doi.org/10.1016/j.celrep.2015.10.052.PubMedPubMedCentralCrossRef

38.

Slessareva, J. E., Routt, S. M., Temple, B., Bankaitis, V. A., & Dohlman, H. G. (2006). Activation of the phosphatidylinositol 3-kinase Vps34 by a G protein alpha subunit at the endosome. Cell, 126(1), 191–203. https://doi.org/10.1016/j.cell.2006.04.045.PubMedCrossRef

39.

Kihara, A., Noda, T., Ishihara, N., & Ohsumi, Y. (2001). Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. The Journal of Cell Biology, 152(3), 519–530.PubMedPubMedCentralCrossRef

40.

Devereaux, K., Dall'Armi, C., Alcazar-Roman, A., Ogasawara, Y., Zhou, X., Wang, F., et al. (2013). Regulation of mammalian autophagy by class II and III PI 3-kinases through PI3P synthesis. PLoS One, 8(10), e76405. https://doi.org/10.1371/journal.pone.0076405.PubMedPubMedCentralCrossRef

41.

Viaud, J., Chicanne, G., Solinhac, R., Hnia, K., Gaits-Iacovoni, F., & Payrastre, B. (2017). Mass assays to quantify bioactive PtdIns3P and PtdIns5P during Autophagic responses. Methods in Enzymology, 587, 293–310. https://doi.org/10.1016/bs.mie.2016.09.061.PubMedCrossRef

42.

Chicanne, G., Severin, S., Boscheron, C., Terrisse, A. D., Gratacap, M. P., Gaits-Iacovoni, F., et al. (2012). A novel mass assay to quantify the bioactive lipid PtdIns3P in various biological samples. The Biochemical Journal, 447(1), 17–23. https://doi.org/10.1042/BJ20120945.PubMedPubMedCentralCrossRef

43.

Maffucci, T., Brancaccio, A., Piccolo, E., Stein, R. C., & Falasca, M. (2003). Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. The EMBO Journal, 22(16), 4178–4189. https://doi.org/10.1093/emboj/cdg402.PubMedPubMedCentralCrossRef

44.

Maffucci, T., Cooke, F. T., Foster, F. M., Traer, C. J., Fry, M. J., & Falasca, M. (2005). Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. The Journal of Cell Biology, 169(5), 789–799. https://doi.org/10.1083/jcb.200408005.PubMedPubMedCentralCrossRef

45.

Lenoir, M., Ustunel, C., Rajesh, S., Kaur, J., Moreau, D., Gruenberg, J., et al. (2018). Phosphorylation of conserved phosphoinositide binding pocket regulates sorting nexin membrane targeting. Nature Communications, 9(1), 993. https://doi.org/10.1038/s41467-018-03370-1.PubMedPubMedCentralCrossRef

46.

Catimel, B., Kapp, E., Yin, M. X., Gregory, M., Wong, L. S., Condron, M., et al. (2013). The PI(3)P interactome from a colon cancer cell. Journal of Proteomics, 82, 35–51. https://doi.org/10.1016/j.jprot.2013.01.031.PubMedCrossRef

47.

Schink, K. O., Raiborg, C., & Stenmark, H. (2013). Phosphatidylinositol 3-phosphate, a lipid that regulates membrane dynamics, protein sorting and cell signalling. Bioessays, 35(10), 900–912. https://doi.org/10.1002/bies.201300064.PubMedCrossRef

48.

Proikas-Cezanne, T., Takacs, Z., Donnes, P., & Kohlbacher, O. (2015). WIPI proteins: essential PtdIns3P effectors at the nascent autophagosome. Journal of Cell Science, 128(2), 207–217. https://doi.org/10.1242/jcs.146258.PubMedCrossRef

49.

Dominguez, V., Raimondi, C., Somanath, S., Bugliani, M., Loder, M. K., Edling, C. E., et al. (2011). Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells. The Journal of Biological Chemistry, 286(6), 4216–4225. https://doi.org/10.1074/jbc.M110.200295.PubMedCrossRef

50.

Ellson, C., Davidson, K., Anderson, K., Stephens, L. R., & Hawkins, P. T. (2006). PtdIns3P binding to the PX domain of p40phox is a physiological signal in NADPH oxidase activation. The EMBO Journal, 25(19), 4468–4478. https://doi.org/10.1038/sj.emboj.7601346.PubMedPubMedCentralCrossRef

51.

Sagona, A. P., Nezis, I. P., Pedersen, N. M., Liestol, K., Poulton, J., Rusten, T. E., et al. (2010). PtdIns(3)P controls cytokinesis through KIF13A-mediated recruitment of FYVE-CENT to the midbody. Nature Cell Biology, 12(4), 362–371. https://doi.org/10.1038/ncb2036.PubMedCrossRef

52.

Clark, J., Anderson, K. E., Juvin, V., Smith, T. S., Karpe, F., Wakelam, M. J., et al. (2011). Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nature Methods, 8(3), 267–272. https://doi.org/10.1038/nmeth.1564.PubMedPubMedCentralCrossRef

53.

Malek, M., Kielkowska, A., Chessa, T., Anderson, K. E., Barneda, D., Pir, P., et al. (2017). PTEN regulates PI(3,4)P2 signaling downstream of class I PI3K. Molecular Cell, 68(3), 566–580 e510. https://doi.org/10.1016/j.molcel.2017.09.024.PubMedPubMedCentralCrossRef

54.

Sugimoto, Y., Whitman, M., Cantley, L. C., & Erikson, R. L. (1984). Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proceedings of the National Academy of Sciences of the United States of America, 81(7), 2117–2121.PubMedPubMedCentralCrossRef

55.

Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L., & Roberts, T. M. (1985). Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature, 315(6016), 239–242.PubMedCrossRef

56.

Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., & Cantley, L. C. (1989). PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell, 57(1), 167–175.PubMedCrossRef

57.

Whitman, M., Downes, C. P., Keeler, M., Keller, T., & Cantley, L. (1988). Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature, 332(6165), 644–646. https://doi.org/10.1038/332644a0.PubMedCrossRef

58.

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304(5670), 554. https://doi.org/10.1126/science.1096502.PubMedCrossRef

59.

Zhao, L., & Vogt, P. K. (2008). Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 105(7), 2652–2657. https://doi.org/10.1073/pnas.0712169105.PubMedPubMedCentralCrossRef

60.

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018). Targeting the PI3K pathway in cancer: are we making headway? Nature Reviews. Clinical Oncology. https://doi.org/10.1038/nrclinonc.2018.28.

61.

Wang, D., Li, C., Zhang, Y., Wang, M., Jiang, N., Xiang, L., et al. (2016). Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecologic Oncology, 142(3), 548–556. https://doi.org/10.1016/j.ygyno.2016.07.092.PubMedPubMedCentralCrossRef

62.

Keppler-Noreuil, K. M., Parker, V. E., Darling, T. N., & Martinez-Agosto, J. A. (2016). Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 172(4), 402–421. https://doi.org/10.1002/ajmg.c.31531.PubMedPubMedCentralCrossRef

63.

Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017). The PI3K pathway in human disease. Cell, 170(4), 605–635. https://doi.org/10.1016/j.cell.2017.07.029.PubMedPubMedCentralCrossRef

64.

Manning, B. D., & Toker, A. (2017). AKT/PKB signaling: navigating the network. Cell, 169(3), 381–405. https://doi.org/10.1016/j.cell.2017.04.001.PubMedPubMedCentralCrossRef

65.

Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 448(7152), 439–444. https://doi.org/10.1038/nature05933.PubMedCrossRef

66.

Srijakotre, N., Man, J., Ooms, L. M., Lucato, C. M., Ellisdon, A. M., & Mitchell, C. A. (2017). P-Rex1 and P-Rex2 RacGEFs and cancer. Biochemical Society Transactions, 45(4), 963–977. https://doi.org/10.1042/BST20160269.PubMedCrossRef

67.

Arnason, J. E., & Brown, J. R. (2017). Targeting B cell signaling in chronic lymphocytic leukemia. Current Oncology Reports, 19(9), 61. https://doi.org/10.1007/s11912-017-0620-7.PubMedCrossRef

68.

Jain, N., & O'Brien, S. (2016). Targeted therapies for CLL: practical issues with the changing treatment paradigm. Blood Reviews, 30(3), 233–244. https://doi.org/10.1016/j.blre.2015.12.002.PubMedCrossRef

69.

Milne, S. B., Ivanova, P. T., DeCamp, D., Hsueh, R. C., & Brown, H. A. (2005). A targeted mass spectrometric analysis of phosphatidylinositol phosphate species. Journal of Lipid Research, 46(8), 1796–1802. https://doi.org/10.1194/jlr.D500010-JLR200.PubMedCrossRef

70.

Naguib, A., Bencze, G., Engle, D. D., Chio, I. I., Herzka, T., Watrud, K., et al. (2015). p53 mutations change phosphatidylinositol acyl chain composition. Cell Reports, 10(1), 8–19. https://doi.org/10.1016/j.celrep.2014.12.010.PubMedCrossRef

71.

Carmona, G., Perera, U., Gillett, C., Naba, A., Law, A. L., Sharma, V. P., et al. (2016). Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. Oncogene, 35(39), 5155–5169. https://doi.org/10.1038/onc.2016.47.PubMedPubMedCentralCrossRef

72.

Paterson, E. K., & Courtneidge, S. A. (2018). Invadosomes are coming: New insights into function and disease relevance. The FEBS Journal, 285(1), 8–27. https://doi.org/10.1111/febs.14123.PubMedCrossRef

73.

Liu, P., Morrison, C., Wang, L., Xiong, D., Vedell, P., Cui, P., et al. (2012). Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis, 33(7), 1270–1276. https://doi.org/10.1093/carcin/bgs148.PubMedPubMedCentralCrossRef

74.

Kind, M., Klukowska-Rotzler, J., Berezowska, S., Arcaro, A., & Charles, R. P. (2017). Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis. PLoS One, 12(10), e0187308. https://doi.org/10.1371/journal.pone.0187308.PubMedPubMedCentralCrossRef

75.

Fukumoto, M., Ijuin, T., & Takenawa, T. (2017). PI(3,4)P2 plays critical roles in the regulation of focal adhesion dynamics of MDA-MB-231 breast cancer cells. Cancer Science, 108(5), 941–951. https://doi.org/10.1111/cas.13215.PubMedPubMedCentralCrossRef

76.

Shaughnessy, R., & Echard, A. (2018). Rab35 GTPase and cancer: linking membrane trafficking to tumorigenesis. Traffic, 19(4), 247–252. https://doi.org/10.1111/tra.12546.PubMedCrossRef

77.

Mosesson, Y., Mills, G. B., & Yarden, Y. (2008). Derailed endocytosis: an emerging feature of cancer. Nature Reviews. Cancer, 8(11), 835–850. https://doi.org/10.1038/nrc2521.PubMedCrossRef

78.

Nascimbeni, A. C., Codogno, P., & Morel, E. (2017). Phosphatidylinositol-3-phosphate in the regulation of autophagy membrane dynamics. The FEBS Journal, 284(9), 1267–1278. https://doi.org/10.1111/febs.13987.PubMedCrossRef

79.

Rubinsztein, D. C., Codogno, P., & Levine, B. (2012). Autophagy modulation as a potential therapeutic target for diverse diseases. Nature Reviews. Drug Discovery, 11(9), 709–730. https://doi.org/10.1038/nrd3802.PubMedPubMedCentralCrossRef

80.

Janku, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011). Autophagy as a target for anticancer therapy. Nature Reviews. Clinical Oncology, 8(9), 528–539. https://doi.org/10.1038/nrclinonc.2011.71.PubMedCrossRef

81.

Das, C. K., Mandal, M., & Kogel, D. (2018). Pro-survival autophagy and cancer cell resistance to therapy. Cancer Metastasis Reviews. https://doi.org/10.1007/s10555-018-9727-z.

82.

Pasquier, B., El-Ahmad, Y., Filoche-Romme, B., Dureuil, C., Fassy, F., Abecassis, P. Y., et al. (2015). Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)- 3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. Journal of Medicinal Chemistry, 58(1), 376–400. https://doi.org/10.1021/jm5013352.PubMedCrossRef

83.

Pasquier, B. (2015). SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells. Autophagy, 11(4), 725–726. https://doi.org/10.1080/15548627.2015.1033601.PubMedPubMedCentralCrossRef

84.

Dowdle, W. E., Nyfeler, B., Nagel, J., Elling, R. A., Liu, S., Triantafellow, E., et al. (2014). Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nature Cell Biology, 16(11), 1069–1079. https://doi.org/10.1038/ncb3053.PubMedCrossRef

85.

Gratacap, M. P., Payrastre, B., Viala, C., Mauco, G., Plantavid, M., & Chap, H. (1998). Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-gamma2 is an early key event in FcgammaRIIA-mediated activation of human platelets. The Journal of Biological Chemistry, 273(38), 24314–24321.PubMedCrossRef

86.

Pasquet, J. M., Bobe, R., Gross, B., Gratacap, M. P., Tomlinson, M. G., Payrastre, B., et al. (1999). A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets. The Biochemical Journal, 342(Pt 1), 171–177.PubMedPubMedCentralCrossRef

87.

Trumel, C., Payrastre, B., Plantavid, M., Hechler, B., Viala, C., Presek, P., et al. (1999). A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood, 94(12), 4156–4165.PubMed

88.

Sultan, C., Plantavid, M., Bachelot, C., Grondin, P., Breton, M., Mauco, G., et al. (1991). Involvement of platelet glycoprotein IIb-IIIa (alpha IIb-beta 3 integrin) in thrombin-induced synthesis of phosphatidylinositol 3′,4′-bisphosphate. The Journal of Biological Chemistry, 266(35), 23554–23557.PubMed

89.

Kurosu, H., Maehama, T., Okada, T., Yamamoto, T., Hoshino, S., Fukui, Y., et al. (1997). Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide. The Journal of Biological Chemistry, 272(39), 24252–24256.PubMedCrossRef

90.

Canobbio, I., Stefanini, L., Cipolla, L., Ciraolo, E., Gruppi, C., Balduini, C., et al. (2009). Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood, 114(10), 2193–2196. https://doi.org/10.1182/blood-2009-03-208074.PubMedCrossRef

91.

Banfic, H., Downes, C. P., & Rittenhouse, S. E. (1998). Biphasic activation of PKBalpha/Akt in platelets. Evidence for stimulation both by phosphatidylinositol 3,4-bisphosphate, produced via a novel pathway, and by phosphatidylinositol 3,4,5-trisphosphate. The Journal of Biological Chemistry, 273(19), 11630–11637.PubMedCrossRef

92.

Woulfe, D., Jiang, H., Morgans, A., Monks, R., Birnbaum, M., & Brass, L. F. (2004). Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. The Journal of Clinical Investigation, 113(3), 441–450.PubMedPubMedCentralCrossRef

93.

Hers, I., Vincent, E. E., & Tavare, J. M. (2011). Akt signalling in health and disease. Cellular Signalling, 23(10), 1515–1527. https://doi.org/10.1016/j.cellsig.2011.05.004.PubMedCrossRef

94.

Moore, S. F., van den Bosch, M. T., Hunter, R. W., Sakamoto, K., Poole, A. W., & Hers, I. (2013). Dual regulation of glycogen synthase kinase 3 (GSK3)alpha/beta by protein kinase C (PKC)alpha and Akt promotes thrombin-mediated integrin alphaIIbbeta3 activation and granule secretion in platelets. The Journal of Biological Chemistry, 288(6), 3918–3928. https://doi.org/10.1074/jbc.M112.429936.PubMedCrossRef

95.

Gratacap, M. P., Herault, J. P., Viala, C., Ragab, A., Savi, P., Herbert, J. M., et al. (2000). FcgammaRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. Blood, 96(10), 3439–3446.PubMed

96.

Ragab, A., Severin, S., Gratacap, M. P., Aguado, E., Malissen, M., Jandrot-Perrus, M., et al. (2007). Roles of the C-terminal tyrosine residues of LAT in GPVI-induced platelet activation: Insights into the mechanism of PLC gamma 2 activation. Blood, 110(7), 2466–2474.PubMedCrossRef

97.

Falasca, M., Logan, S. K., Lehto, V. P., Baccante, G., Lemmon, M. A., & Schlessinger, J. (1998). Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. The EMBO Journal, 17(2), 414–422. https://doi.org/10.1093/emboj/17.2.414.PubMedPubMedCentralCrossRef

98.

Bae, Y. S., Cantley, L. G., Chen, C. S., Kim, S. R., Kwon, K. S., & Rhee, S. G. (1998). Activation of phospholipase C-gamma by phosphatidylinositol 3,4,5-trisphosphate. The Journal of Biological Chemistry, 273(8), 4465–4469.PubMedCrossRef

99.

Wang, Y., & Wang, Z. (2003). Regulation of EGF-induced phospholipase C-gamma1 translocation and activation by its SH2 and PH domains. Traffic, 4(9), 618–630.PubMedCrossRef

100.

Stefanini, L., Roden, R. C., & Bergmeier, W. (2009). CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood, 114(12), 2506–2514. https://doi.org/10.1182/blood-2009-04-218768.PubMedCrossRef

101.

Chrzanowska-Wodnicka, M., Smyth, S. S., Schoenwaelder, S. M., Fischer, T. H., & White 2nd, G. C. (2005). Rap1b is required for normal platelet function and hemostasis in mice. The Journal of Clinical Investigation, 115(3), 680–687. https://doi.org/10.1172/JCI22973.PubMedPubMedCentralCrossRef

102.

Schurmans, S., Polizzi, S., Scoumanne, A., Sayyed, S., & Molina-Ortiz, P. (2015). The Ras/Rap GTPase activating protein RASA3: from gene structure to in vivo functions. Advances in Biological Regulation, 57, 153–161. https://doi.org/10.1016/j.jbior.2014.09.006.PubMedCrossRef

103.

Stefanini, L., Paul, D. S., Robledo, R. F., Chan, E. R., Getz, T. M., Campbell, R. A., et al. (2015). RASA3 is a critical inhibitor of RAP1-dependent platelet activation. The Journal of Clinical Investigation, 125(4), 1419–1432. https://doi.org/10.1172/JCI77993.PubMedPubMedCentralCrossRef

104.

Lova, P., Paganini, S., Hirsch, E., Barberis, L., Wymann, M., Sinigaglia, F., et al. (2003). A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. The Journal of Biological Chemistry, 278(1), 131–138. https://doi.org/10.1074/jbc.M204821200.PubMedCrossRef

105.

Guidetti, G. F., & Torti, M. (2012). The small GTPase Rap1b: a bidirectional regulator of platelet adhesion receptors. Journal of Signal Transduction, 2012, 412089. https://doi.org/10.1155/2012/412089.PubMedPubMedCentralCrossRef

106.

Quek, L. S., Bolen, J., & Watson, S. P. (1998). A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Current Biology, 8(20), 1137–1140.PubMedCrossRef

107.

Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J. T., Danilov, A. V., & DeLoughery, T. G. (2017). Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. Journal of Thrombosis and Haemostasis, 15(5), 835–847. https://doi.org/10.1111/jth.13651.PubMedCrossRef

108.

Dowler, S., Currie, R. A., Downes, C. P., & Alessi, D. R. (1999). DAPP1: a dual adaptor for phosphotyrosine and 3-phosphoinositides. The Biochemical Journal, 342(Pt 1), 7–12.PubMedPubMedCentralCrossRef

109.

Huang, Y., Joshi, S., Xiang, B., Kanaho, Y., Li, Z., Bouchard, B. A., et al. (2016). Arf6 controls platelet spreading and clot retraction via integrin alphaIIbbeta3 trafficking. Blood, 127(11), 1459–1467. https://doi.org/10.1182/blood-2015-05-648550.PubMedPubMedCentralCrossRef

110.

Rondina, M. T., & Weyrich, A. S. (2016). Arf6 arbitrates fibrinogen endocytosis. Blood, 127(11), 1383–1384. https://doi.org/10.1182/blood-2016-01-692145.PubMedPubMedCentralCrossRef

111.

van den Bosch, M. T., Poole, A. W., & Hers, I. (2014). Cytohesin-2 phosphorylation by protein kinase C relieves the constitutive suppression of platelet dense granule secretion by ADP-ribosylation factor 6. Journal of Thrombosis and Haemostasis, 12(5), 726–735. https://doi.org/10.1111/jth.12542.PubMedPubMedCentralCrossRef

112.

Nylander, S., Kull, B., Bjorkman, J. A., Ulvinge, J. C., Oakes, N., Emanuelsson, B. M., et al. (2012). Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. Journal of Thrombosis and Haemostasis, 10(10), 2127–2136. https://doi.org/10.1111/j.1538-7836.2012.04898.x.PubMedCrossRef

113.

Nylander, S., Wagberg, F., Andersson, M., Skarby, T., & Gustafsson, D. (2015). Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase beta inhibition and aspirin in man. Journal of Thrombosis and Haemostasis, 13(8), 1494–1502. https://doi.org/10.1111/jth.13027.PubMedCrossRef

114.

Giuriato, S., Payrastre, B., Drayer, A. L., Plantavid, M., Woscholski, R., Parker, P., et al. (1997). Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombin-stimulated human blood platelets. The Journal of Biological Chemistry, 272(43), 26857–26863.PubMedCrossRef

115.

Giuriato, S., Bodin, S., Erneux, C., Woscholski, R., Plantavid, M., Chap, H., et al. (2000). pp60c-src associates with the SH2-containing inositol-5-phosphatase SHIP1 and is involved in its tyrosine phosphorylation downstream of alphaIIbbeta3 integrin in human platelets. The Biochemical Journal, 348(Pt 1), 107–112.PubMedPubMedCentralCrossRef

116.

Severin, S., Gratacap, M. P., Lenain, N., Alvarez, L., Hollande, E., Penninger, J. M., et al. (2007). Deficiency of Src homology 2 domain-containing inositol 5-phosphatase 1 affects platelet responses and thrombus growth. The Journal of Clinical Investigation, 117(4), 944–952.PubMedPubMedCentralCrossRef

117.

Giuriato, S., Pesesse, X., Bodin, S., Sasaki, T., Viala, C., Marion, E., et al. (2003). SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels. The Biochemical Journal, 376(Pt 1), 199–207. https://doi.org/10.1042/BJ20030581. PubMedPubMedCentralCrossRef

118.

Burkhart, J. M., Vaudel, M., Gambaryan, S., Radau, S., Walter, U., Martens, L., et al. (2012). The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood, 120(15), e73–e82. https://doi.org/10.1182/blood-2012-04-416594.PubMedCrossRef

119.

Valet, C., Levade, M., Chicanne, G., Bilanges, B., Cabou, C., Viaud, J., et al. (2017). A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth. Blood. https://doi.org/10.1182/blood-2017-04-781641.

120.

Mountford, J. K., Petitjean, C., Putra, H. W., McCafferty, J. A., Setiabakti, N. M., Lee, H., et al. (2015). The class II PI 3-kinase, PI3KC2alpha, links platelet internal membrane structure to shear-dependent adhesive function. Nature Communications, 6, 653/5. https://doi.org/10.1038/ncomms7535.CrossRef

121.

Zhang, J., Banfic, H., Straforini, F., Tosi, L., Volinia, S., & Rittenhouse, S. E. (1998). A type II phosphoinositide 3-kinase is stimulated via activated integrin in platelets. A source of phosphatidylinositol 3-phosphate. The Journal of Biological Chemistry, 273(23), 14081–14084.PubMedCrossRef

122.

Liu, Y., Hu, M., Luo, D., Yue, M., Wang, S., Chen, X., et al. (2017). Class III PI3K positively regulates platelet activation and thrombosis via PI(3)P-directed function of NADPH oxidase. Arteriosclerosis, Thrombosis, and Vascular Biology, 37(11), 2075–2086. https://doi.org/10.1161/ATVBAHA.117.309751.PubMedCrossRef

Titel: The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis
verfasst von: Typhaine Anquetil
Bernard Payrastre
Marie-Pierre Gratacap
Julien Viaud
Publikationsdatum: 04.06.2018
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2-3/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9735-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2018

Biographies

Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells

Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond

Triumph and tumult of matrix metalloproteinases and their crosstalk with eicosanoids in cancer

Role of autotaxin in cancer stem cells

Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie